Prognostic factors for survival in metastatic renal cell carcinoma : Update 2008
β Scribed by Ronald M. Bukowski
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 270 KB
- Volume
- 115
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The authors thank S. Ne Β΄grier, M.D., A. Ravaud, M.D., and G. Chvetzoff for providing the clinical charts of patients included in the external data set.
## Abstract ## BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferonβalfa as firstβline therapy in patients with metastatic clearβcell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predi
cause they may be impractical, expensive, or unproven. Group II is an intermediate group expected to be available in the near future and Presented at ''Diagnosis and Prognosis of Renal characterized by greater requirements for time, money, and other Cell Carcinoma: 1997 Workshop,'' Rochester, resour